This phase 2, randomized, open label study will investigate the efficacy of VGX-3100 followed by electroporation (EP) with CELLECTRA® 2000 alone or in combination with imiquimod in participants with human papillomavirus (HPV)-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the vulva.